ARRAYIT CORPORATION ANNOUNCES THE RELEASE OF H25K HUMAN GENOME CHIP
01/29/2011

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.

Online PR News – 29-January-2011 – – SUNNYVALE, Calif.-- Arrayit Corporation (OTCBB: ARYC), a leader of proprietary life science technologies founded on the Company’s vast microarray technology products, announced today that it has designed and manufactured a microarray, labeled H25K, that utilizes the complete human genome sequence. H25K allows for the biological exploration across 25,509 annotated human genes and over 300,000 gene transcripts.

Designed with 26,304 long oligonucleotides, including industry recognized controls, users can utilize samples prepared from genomic DNA, mRNA and protein to study problems ranging from karyotyping and gene expression profiling to chromatin structure and protein-DNA interactions. For gene expression uses, Arrayit’s revolutionary one spot-one geneTM design allows the quantitative measurement of over 300,000 human transcripts in a single hybridization reaction.

Unprecedented specificity and sensitivity is achieved using advanced bioinformatics, oligonucleotide manufacturing, microarray printing, and surface chemistry. Thus, allowing streamlined data analysis and mining. Fully compatible with all standard format microarray slide scanners, H25K sets a new standard for human genome microarrays.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 800 products to a customer base of more than 3,800 institutions covering 10,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit http://www.arrayit.com for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2009 and Form 10-Q for the fiscal quarter ended September 30, 2010.

Contact:
Steven Scott
Issuers Capital Advisors, LLC
480-767-7733